

CORRESPONDENCE

Number needed to treat in COPD: exacerbations versus pneumonias

Number needed to treat (NNT) is an attractive concept for clinicians, but its application to a treatment that reduces the frequency of COPD exacerbations is not straightforward. Dr Suissa¹ proposes a method for calculating the NNT based on the Kaplan–Meier curve of time to first exacerbation. This approach ignores all exacerbations beyond the first one experienced by the patient and does not appropriately reflect the benefit of a treatment that reduces multiple exacerbations in the same patient.² From a statistical viewpoint, the approach is not efficient as it does not use all the exacerbation data collected. Dr Suissa has himself previously advocated methods of analysis of exacerbations that account for multiple events.³

The paper states that ‘the proper calculation resulted in a NNT of 14 patients who need to be treated for 1 year to prevent one COPD exacerbation’. This interpretation of the patient-based NNT is incorrect. As the only data used is the time of the first exacerbation, the calculation performed is of the NNT needed to prevent one patient from experiencing any exacerbations in the year.

For the Towards a Revolution in COPD Health (TORCH) study, the author converts event rates to probabilities of an event using a formula based on the Poisson distribution, which does not account for the correlation of events within an individual. This calculation gives incorrect estimates of incidence rates and, therefore, the patient-based NNT for TORCH is considerably wrong. This error is surprising as Dr Suissa has criticised others for neglecting this extra-Poisson variability.³ The Investigating New Standards for Prophylaxis in Reducing Exacerbations (INSPIRE) study⁴ compared two active treatments, not simply an ICS treatment versus no use of ICS, so it is misleading to include this study in table 2 of the paper.

Using a single point from a Kaplan–Meier curve to estimate the probability of an exacerbation reduces a complex dataset to the dichotomous presence or absence of at least one exacerbation in that time interval. Statisticians, Senn and Julious,⁵ have criticised this practice stating: ‘it is totally unacceptable to create dichotomies purely in order to be able to calculate NNTs’. In the extreme, if all patients experience at

least one event, then the patient-based NNT is infinite.

In summary, the patient-based NNT does not accurately describe the benefit of a treatment that reduces the frequency of exacerbations. We believe that this requires a statistical analysis² that recognises the repeated nature of these events, as Dr Suissa has previously recommended.

Oliver N Keene,¹ Antonio Anzueto,²
Gary T Ferguson,³ Peter M A Calverley⁴

¹Clinical Statistics, GlaxoSmithKline, Uxbridge, UK

²Pulmonary/Critical Care Division, University of Texas Health Science Center, San Antonio, Texas, USA

³Pulmonary Research Institute of Southeast Michigan, Livonia, Michigan, USA

⁴School of Aging and Chronic Disease, University of Liverpool, Liverpool, UK

Correspondence to Oliver N Keene, Clinical Statistics, GlaxoSmithKline, 1-3 Iron Bridge Road, Uxbridge UB11 1BT, UK; oliver.n.keene@gsk.com

Contributors All authors contributed to the content of this letter.

Competing interests ONK is an employee of GlaxoSmithKline and owns shares and share options in GlaxoSmithKline. GTF has received consultancy fees from GlaxoSmithKline, Boehringer Ingelheim, Forest, AstraZeneca, Pearl Therapeutics and Sunovion; received grants from Boehringer Ingelheim, Novartis, Forest, Pearl Therapeutics, GlaxoSmithKline and Pfizer and lecturing fees from GlaxoSmithKline, Boehringer Ingelheim and Forest. AA has received consultancy fees and lecturing fees from GlaxoSmithKline, Dey Pharma, Pfizer, Boehringer Ingelheim, Bayer-Schering Pharma and AstraZeneca. PMAC has received consultancy fees from GlaxoSmithKline and Novartis; consultancy fees from Nycomed and Boehringer Ingelheim; lecturing fees from Novartis, Pfizer, GlaxoSmithKline, AstraZeneca and Takeda Nycomed; travel support from GlaxoSmithKline and Boehringer Ingelheim and payment for providing expert testimony for Forest.

Provenance and peer review Not commissioned; internally peer reviewed.

To cite Keene ON, Anzueto A, Ferguson GT, et al. *Thorax* 2013;**68**:882.

Received 8 February 2013

Accepted 21 February 2013

Published Online First 16 March 2013



► <http://dx.doi.org/10.1136/thoraxjnl-2013-203461>

Thorax 2013;**68**:882.

doi:10.1136/thoraxjnl-2013-203403

REFERENCES

- 1 Suissa S. Number needed to treat in COPD: exacerbations versus pneumonias. *Thorax* 2013;**68**: 540–3.
- 2 Keene ON, Calverley PMA, Jones PW, et al. Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited. *Eur Respir J* 2008;**32**:17–24.
- 3 Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2006;**173**:842–6.

- 4 Wedzicha JA, Calverley PMA, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. *Am J Respir Crit Care Med* 2008;**177**:19–26.
- 5 Senn S, Julious S. Measurement in clinical trials: a neglected issue for statisticians? *Stat Med* 2009;**28**:3189–209.